Medtronic received information via literature regarding transcatheter versus surgical pulmonary valve replacement.All data were collected from a meta-analysis review of 18 published articles found between article inception to january 2019.The study population included 6,071 patients (predominantly male, mean age 21.9 years), whom were implanted with either a non-medtronic or a medtronic melody tpv (no unique device identifier numbers provided).Based on the available information, a death occurred within a tpv group in three of the 18 articles included in the meta-analysis review.Multiple manufacturer¿s devices were implanted in the study population.None of the deaths were directly associated with medtronic product.Based on the available information medtronic product was not directly associated with the death(s).Among all tpv patients, adverse events included: severe pulmonary regurgitation, endocarditis, high transvalvular gradients, pseudo aneurysm, arteriovenous fistula, stent fracture, transcatheter pulmonary valve deployment issue, hemorrhage, hematoma, transient atrioventricular conduction block, conduit perforation, hemothorax/pneumothorax/pleural effusion requiring chest tube, cardiopulmonary arrest with crushed melody valve from chest compressions, infection/fever, and repeat intervention.Based on the available information medtronic product was directly associated with some the adverse event(s).No additional adverse patient effects or product performance issues were reported.
|